Navigation Links
Quanterix Announces Publication of Novel Method Expanding Single Molecule Detection Capability
Date:2/23/2011

CAMBRIDGE, Mass., Feb. 23, 2011 /PRNewswire/ -- Quanterix Corporation, a single molecule diagnostics company providing technology with unprecedented sensitivity for the life science and in vitro diagnostics markets, today announced the online publication of a study that builds upon the company's Single Molecule Array (SiMoA™) technology by combining digital and analog detection in one straightforward measurement.  The article appears in the journal Analytical Chemistry, and highlights the ability to precisely measure proteins present at not only extremely low levels, but higher concentrations as well, effectively extending the dynamic range of immunoassays from the picomolar level down to sub-femtomolar levels in a single measurement.  

"Many diagnostic applications require tests to be sensitive as well as perform over a broad spectrum of concentrations to allow target analytes to be measured in the majority of clinical samples.  By combining the Quanterix digital approach for single molecule detection with ensemble measurements, we are able to measure proteins over a wider range than either method alone," said David Duffy, Ph.D., corresponding author of the article.

David Okrongly, Ph.D., President and CEO of Quanterix added, "The ability to accurately measure proteins over a larger concentration range, down to sub-femtomolar levels, further moves the company towards our stated goal of providing a universal platform that will improve the quality and clinical value of immunodiagnostics.  This expansion of our SiMoA technology allows us to deliver the most sensitive and precise results without sacrificing assay throughput or increasing cost in the clinical setting."

About Quanterix

Quanterix Corporation is developing its proprietary Single Molecule Array (SiMoA™) technology for the in vitro diagnostics and life science research markets. The digital nature of SiMoA yields unprecedented assay performance, stemming from a 1,000-fold improvement in sensitivity compared with today's analog only technology. SiMoA will enable researchers in life science to validate novel, low abundance biomolecules from a single droplet of blood, leading to greater insight into disease detection, diagnosis, therapy selection and disease monitoring. Automated systems based on SiMoA will provide diagnostic test information to healthcare practitioners faster, with greater reliability, unprecedented range and increased cost effectiveness.  Founded in 2007, the privately held Cambridge, Massachusetts-based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures. For additional information, please visit www.quanterix.com.


'/>"/>
SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Quanterix Announces New Technology Evaluation Agreement
2. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
3. Stereotaxis Announces Election of Joseph D. Keegan to Board of Directors
4. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
5. Dendreon Announces Presentation of PROVENGE Data at the 2011 Genitourinary Cancers Symposium Annual Meeting
6. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
7. Sensus Healthcare Announces the Formation of a Medical Advisory Board
8. Sigma-Aldrich Announces Organizational Changes
9. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
10. MiMedx Announces Launch of AmnioFix™
11. Savient Pharmaceuticals Announces Executive Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... (PRWEB) , ... January 20, ... ... in Less Exposure Surgery (LES®) Technologies, announced today the next evolution in ... Pedicle Screw System platform). In contrast to the competition, SpineFrontier is focused ...
(Date:1/19/2017)... , Jan. 19, 2017 /PRNewswire -- WuXi ... device open-access capability and technology platform, today announced ... leading biology focused preclinical drug discovery contract research ... will become a wholly-owned subsidiary of WuXi, and ... competences and providing greater services. The acquisition will ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
Breaking Biology Technology:
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... ALAMEDA, Calif. , Dec. 8, 2016  Singulex, ... Single Molecule Counting technology, entered into a license and ... in serving science. The agreement provides Singulex access to ... Europe is used to diagnose ... the United States to aid in assessing ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
Breaking Biology News(10 mins):